Search

Registration & accommodation

Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

Pediatric Hematology

The SWG on Pediatric Hematology has several key goals for the next four years (2024–2026):

To further develop our role as the voice of pediatric hematology within EHA
To reach out to YEHA pediatric hematologists to develop educational material to underpin our…

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

Highlights of Past EHA (HOPE) Asia 2020

October 16-17 2020
Meeting Chairs:

Dr N Senadheera (Sri Lanka College of Haematologists)
Prof J Gribben (European Hematology Association)

This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020.…

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more